Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-240-7133
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.79 million
Profitability
Miscellaneous
Employees30
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable
Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions
What is Heat Biologics' stock symbol?
Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."
When did Heat Biologics' stock split? How did Heat Biologics' stock split work?
Heat Biologics's stock reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.
How were Heat Biologics' earnings last quarter?
Heat Biologics Inc (NASDAQ:HTBX) announced its earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company had revenue of $0.34 million for the quarter, compared to analysts' expectations of $0.91 million. Heat Biologics had a negative return on equity of 75.51% and a negative net margin of 386.16%. View Heat Biologics' Earnings History.
When is Heat Biologics' next earnings date?
What price target have analysts set for HTBX?
3 analysts have issued 1-year price objectives for Heat Biologics' stock. Their predictions range from $6.00 to $8.00. On average, they anticipate Heat Biologics' share price to reach $6.6667 in the next year. This suggests a possible upside of 1,069.6% from the stock's current price. View Analyst Price Targets for Heat Biologics.
What is the consensus analysts' recommendation for Heat Biologics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics.
Has Heat Biologics been receiving favorable news coverage?
News articles about HTBX stock have trended somewhat negative on Monday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Heat Biologics earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Heat Biologics.
Are investors shorting Heat Biologics?
Heat Biologics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 524,800 shares, an increase of 43.2% from the July 31st total of 366,600 shares. Based on an average trading volume of 340,900 shares, the short-interest ratio is presently 1.5 days. Currently, 1.6% of the company's shares are sold short. View Heat Biologics' Current Options Chain.
Who are some of Heat Biologics' key competitors?
Some companies that are related to Heat Biologics include Selecta Biosciences (SELB), Cumberland Pharmaceuticals (CPIX), Tiziana Life Sciences (TLSA), Synlogic (SYBX), Aquestive Therapeutics (AQST), Eyenovia (EYEN), Neoleukin Therapeutics (NLTX), Alpine Immune Sciences (ALPN), Entasis Therapeutics (ETTX), Merrimack Pharmaceuticals (MACK), Inflarx (IFRX), Lipocine (LPCN), Marinus Pharmaceuticals (MRNS), Novan (NOVN) and NewLink Genetics (NLNK).
What other stocks do shareholders of Heat Biologics own?
Who are Heat Biologics' key executives?
Heat Biologics' management team includes the folowing people:
- Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)
- Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)
- Mr. Robert J. Jakobs, VP of Fin., Sec. & Controller (Age 64)
- Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory Board
- Colonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor
Who are Heat Biologics' major shareholders?
Which institutional investors are buying Heat Biologics stock?
How do I buy shares of Heat Biologics?
Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Heat Biologics' stock price today?
One share of HTBX stock can currently be purchased for approximately $0.57.
How big of a company is Heat Biologics?
Heat Biologics has a market capitalization of $19.42 million and generates $5.79 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Heat Biologics employs 30 workers across the globe.View Additional Information About Heat Biologics.
What is Heat Biologics' official website?
How can I contact Heat Biologics?
Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]
MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)
MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
